Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs

Ekaterina V. Kurbatova*, J. S. Cavanaugh, N. S. Shah, A. Wright, H. Kim, B. Metchock, A. Van Deun, L. Barrera, F. Boulahbal, E. Richter, N. Martín-Casabona, F. Arias, I. Zemanova, Francis Drobniewski, A. Santos Silva, C. Coulter, R. Lumb, J. P. Cegielski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not a lways a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistanceassociated DNA mutations.

Original languageEnglish
Pages (from-to)355-357
Number of pages3
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number3
Publication statusPublished - 1 Mar 2012

Bibliographical note

Copyright 2013 Elsevier B.V., All rights reserved.


  • Drug resistance
  • Molecular diagnostic tests
  • Rifampicin resistance
  • Tuberculosis


Dive into the research topics of 'Rifampicin-resistant Mycobacterium tuberculosis: Susceptibility to isoniazid and other anti-tuberculosis drugs'. Together they form a unique fingerprint.

Cite this